drugset / Trial / NCT00793650
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug used to treat myeloma.
Timeline
- Start
- 2005-05
- Primary completion
- 2009-10
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1 mg/m2 | — |
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Comparator | Bortezomib | Small molecule | 1.6 mg/m2 | — |
| Comparator | Melphalan | Small molecule | 100 mg/m2 | — |